West Nile fever explained

West Nile fever
Field:Infectious disease
Symptoms:None, fever, headache, vomiting or diarrhea and muscle aches rash
Complications:Encephalitis, meningitis
Onset:2 to 14 days after exposure
Duration:Weeks to months
Causes:West Nile virus spread by mosquito
Diagnosis:Based on symptoms and blood tests
Prevention:Reducing mosquitoes, preventing mosquito bites
Treatment:Supportive care (pain medication)
Prognosis:10% risk of death among those seriously affected

West Nile fever is an infection by the West Nile virus, which is typically spread by mosquitoes.[1] In about 80% of infections people have few or no symptoms.[2] About 20% of people develop a fever, headache, vomiting, or a rash.[1] In less than 1% of people, encephalitis or meningitis occurs, with associated neck stiffness, confusion, or seizures.[1] Recovery may take weeks to months.[1] The risk of death among those in whom the nervous system is affected is about 10 percent.[1]

West Nile virus (WNV) is usually spread by mosquitoes that become infected when they feed on infected birds, which often carry the disease.[1] Rarely the virus is spread through blood transfusions, organ transplants, or from mother to baby during pregnancy, delivery, or breastfeeding,[1] but it otherwise does not spread directly between people. Risks for severe disease include being over 60 years old and having other health problems.[1] Diagnosis is typically based on symptoms and blood tests.[1]

There is no human vaccine.[1] The best way to reduce the risk of infection is to avoid mosquito bites.[1] Mosquito populations may be reduced by eliminating standing pools of water, such as in old tires, buckets, gutters, and swimming pools.[1] When mosquitoes cannot be avoided, mosquito repellent, window screens, and mosquito nets reduce the likelihood of being bitten.[1] There is no specific treatment for the disease; pain medications may reduce symptoms.[1]

The virus was discovered in Uganda in 1937, and was first detected in North America in 1999.[1] WNV has occurred in Europe, Africa, Asia, Australia, and North America.[1] In the United States thousands of cases are reported a year, with most occurring in August and September.[3] It can occur in outbreaks of disease. Severe disease may also occur in horses, for which a vaccine is available.[4] A surveillance system in birds is useful for early detection of a potential human outbreak.[4]

Signs and symptoms

About 80% of those infected with West Nile virus (WNV) show no symptoms and go unreported.[5] About 20% of infected people develop symptoms. These vary in severity, and begin 3 to 14 days after being bitten. Most people with mild symptoms of WNV recover completely, though fatigue and weakness may last for weeks or months. Symptoms may range from mild, such as fever, to severe, such as paralysis and meningitis. A severe infection can last weeks and can, rarely, cause permanent brain damage. Death may ensue if the central nervous system is affected. Medical conditions such as cancer and diabetes, and age over 60 years, increase the risk of developing severe symptoms.[6] [7]

Headache can be a prominent symptom of WNV fever, meningitis, encephalitis, meningoencephalitis, and it may or may not be present in poliomyelitis-like syndrome. Thus, headache is not a useful indicator of neuroinvasive disease.

Cause

Virology

See main article: West Nile virus. WNV is one of the Japanese encephalitis antigenic serocomplex of viruses.[20] Image reconstructions and cryoelectron microscopy reveal a 45–50 nm virion covered with a relatively smooth protein surface. This structure is similar to the dengue fever virus; both belong to the genus Flavivirus within the family Flaviviridae. The genetic material of WNV is a positive-sense, single strand of RNA, which is between 11,000 and 12,000 nucleotides long; these genes encode seven nonstructural proteins and three structural proteins. The RNA strand is held within a nucleocapsid formed from 12-kDa protein blocks; the capsid is contained within a host-derived membrane altered by two viral membrane proteins.[21]

West Nile virus has been seen to replicate faster and spread more easily to birds at higher temperatures; one of several ways climate change could affect the epidemiology of this disease.

Transmission

The prime method of spread of the West Nile virus (WNV) is the female mosquito. In Europe, cats were identified as being hosts for West Nile virus.[22] The important mosquito vectors vary according to area; in the United States, Culex pipiens (Eastern United States, and urban and residential areas of the United States north of 36–39°N), Culex tarsalis (Midwest and West), and Culex quinquefasciatus (Southeast) are the main vector species.[23] In Europe, Culex pipiens is the principal vector.[24]

The mosquito species that are most frequently infected with WNV feed primarily on birds.[25] Different species of mosquitos take a blood meal from different types of vertebrate hosts, Mosquitoes show further selectivity, exhibiting preference for different species of birds. In the United States, WNV mosquito vectors feed preferentially on members of the Corvidae and thrush family. Among the preferred species within these families are the American crow, a corvid, and the American robin (Turdus migratorius).[26]

Some species of birds develop sufficient viral levels (>~104.2 log PFU/ml;[27]) after being infected to transmit the infection to biting mosquitoes that in turn go on to infect other birds. In birds that die from WNV, death usually occurs after 4 to 6 days.[28] In mammals and several species of birds, the virus does not multiply as readily and so does not develop high viremia during infection. Mosquitoes biting such hosts are not believed to ingest sufficient virus to become infected, making them so-called dead-end hosts.[27] As a result of the differential infectiousness of hosts, the feeding patterns of mosquitoes play an important role in WNV transmission,[25] [26] and they are partly genetically controlled, even within a species.[29]

Direct human-to-human transmission initially was believed to be caused only by occupational exposure, such as in a laboratory setting,[30] or conjunctival exposure to infected blood.[31] The US outbreak identified additional transmission methods through blood transfusion,[32] organ transplant,[33] intrauterine exposure,[34] and breast feeding.[35] Since 2003, blood banks in the United States routinely screen for the virus among their donors.[36] As a precautionary measure, the UK's National Blood Service initially ran a test for this disease in donors who donate within 28 days of a visit to the United States, Canada, or the northeastern provinces of Italy, and the Scottish National Blood Transfusion Service[37] asks prospective donors to wait 28 days after returning from North America or the northeastern provinces of Italy before donating. There also have been reports of possible transmission of the virus from mother to child during pregnancy or breastfeeding or exposure to the virus in a lab, but these are rare cases and not conclusively confirmed.[38]

Recently, the potential for mosquito saliva to affect the course of WNV disease was demonstrated.[39] [40] [41] Mosquitoes inoculate their saliva into the skin while obtaining blood. Mosquito saliva is a pharmacological cocktail of secreted molecules, principally proteins, that can affect vascular constriction, blood coagulation, platelet aggregation, inflammation, and immunity. It clearly alters the immune response in a manner that may be advantageous to a virus.[42] [43] [44] [45] Studies have shown it can specifically modulate the immune response during early virus infection,[46] and mosquito feeding can exacerbate WNV infection, leading to higher viremia and more severe forms of disease.[39] [40] [41]

Vertical transmission

Vertical transmission, the transmission of a viral or bacterial disease from the female of the species to her offspring, has been observed in various West Nile virus studies, amongst different species of mosquitoes in both the laboratory and in nature.[47] Mosquito progeny infected vertically in autumn may potentially serve as a mechanism for WNV to overwinter and initiate enzootic horizontal transmission the following spring, although it likely plays little role in transmission in the summer and fall.[48]

Risk factors

Risk factors independently associated with developing a clinical infection with WNV include a suppressed immune system and a patient history of organ transplantation.[49] For neuroinvasive disease the additional risk factors include older age (>50+), male sex, hypertension, and diabetes mellitus.[50] [51]

A genetic factor also appears to increase susceptibility to West Nile disease. A mutation of the gene CCR5 gives some protection against HIV but leads to more serious complications of WNV infection. Carriers of two mutated copies of CCR5 made up 4.0 to 4.5% of a sample of people with West Nile disease, while the incidence of the gene in the general population is only 1.0%.[52] [53]

The most at risk occupations in the U.S. are outdoor workers, for example farmers, loggers, landscapers/groundskeepers, construction workers, painters, summer camp workers and pavers.[54] Two reports of accidental exposure by laboratory personnel working with infected fluids or tissues have been received. While this appears to be a rare occurrence, it highlights the need for proper handling of infected materials. The World Health Organization states that there are no known cases of health care workers acquiring the virus from infected patients when the appropriate infection control precautions are observed.[55]

Diagnosis

Preliminary diagnosis is often based on the patient's clinical symptoms, places and dates of travel (if patient is from a nonendemic country or area), activities, and epidemiologic history of the location where infection occurred. A recent history of mosquito bites and an acute febrile illness associated with neurologic signs and symptoms should cause clinical suspicion of WNV.

Diagnosis of West Nile virus infections is generally accomplished by serologic testing of blood serum or cerebrospinal fluid (CSF), which is obtained via a lumbar puncture. Initial screening could be done using the ELISA technique detecting immunoglobulins in the sera of the tested individuals.[21]

Typical findings of WNV infection include lymphocytic pleocytosis, elevated protein level, reference glucose and lactic acid levels, and no erythrocytes.[56]

Definitive diagnosis of WNV is obtained through detection of virus-specific antibody IgM and neutralizing antibodies. Cases of West Nile virus meningitis and encephalitis that have been serologically confirmed produce similar degrees of CSF pleocytosis and are often associated with substantial CSF neutrophilia.[57] Specimens collected within eight days following onset of illness may not test positive for West Nile IgM, and testing should be repeated. A positive test for West Nile IgG in the absence of a positive West Nile IgM is indicative of a previous flavivirus infection and is not by itself evidence of an acute West Nile virus infection.[58]

If cases of suspected West Nile virus infection, sera should be collected on both the acute andconvalescent phases of the illness. Convalescent specimens should be collected 2–3 weeks after acute specimens.

It is common in serologic testing for cross-reactions to occur among flaviviruses such as dengue virus (DENV) and tick-borne encephalitis virus; this necessitates caution when evaluating serologic results of flaviviral infections.[59]

Four FDA-cleared WNV IgM ELISA kits are commercially available from different manufacturers in the U.S., each of these kits is indicated for use on serum to aid in the presumptive laboratory diagnosis of WNV infection in patients with clinical symptoms of meningitis or encephalitis. Positive WNV test results obtained via use of these kits should be confirmed by additional testing at a state health department laboratory or CDC.[60]

In fatal cases, nucleic acid amplification, histopathology with immunohistochemistry, and virus culture of autopsy tissues can also be useful. Only a few state laboratories or other specialized laboratories, including those at CDC, are capable of doing this specialized testing.[61]

Differential diagnosis

A number of various diseases may present with symptoms similar to those caused by a clinical West Nile virus infection. Those causing neuroinvasive disease symptoms include the enterovirus infection and bacterial meningitis. Accounting for differential diagnoses is a crucial step in the definitive diagnosis of WNV infection. Consideration of a differential diagnosis is required when a patient presents with unexplained febrile illness, extreme headache, encephalitis or meningitis. Diagnostic and serologic laboratory testing using polymerase chain reaction (PCR) testing and viral culture of CSF to identify the specific pathogen causing the symptoms, is the only currently available means of differentiating between causes of encephalitis and meningitis.[21]

Prevention

Many of the guidelines for preventing occupational West Nile virus exposure are common to all mosquito-borne diseases.[62]

Public health measures include taking steps to reduce mosquito populations. Personal recommendations are to reduce the likelihood of being bitten. General measures to avoid bites include:

Monitoring and control

West Nile virus can be sampled from the environment by the pooling of trapped mosquitoes via ovitraps, carbon dioxide-baited light traps, and gravid traps, testing blood samples drawn from wild birds, dogs, and sentinel monkeys, and testing brains of dead birds found by various animal control agencies and the public.

Testing of the mosquito samples requires the use of reverse-transcriptase PCR (RT-PCR) to directly amplify and show the presence of virus in the submitted samples. When using the blood sera of wild birds and sentinel chickens, samples must be tested for the presence of WNV antibodies by use of immunohistochemistry (IHC)[67] or enzyme-linked immunosorbent assay (ELISA).[68]

Dead birds, after necropsy, or their oral swab samples collected on specific RNA-preserving filter paper card,[69] [70] can have their virus presence tested by either RT-PCR or IHC, where virus shows up as brown-stained tissue because of a substrate-enzyme reaction.

West Nile control is achieved through mosquito control, by elimination of mosquito breeding sites such as abandoned pools, applying larvacide to active breeding areas, and targeting the adult population via lethal ovitraps and aerial spraying of pesticides.[71] [72] [73] With aerial pesticides, there is a rising need to develop new versions as pesticide resistance among mosquitoes can occur.[74] [75]

Environmentalists have condemned attempts to control the transmitting mosquitoes by spraying pesticide, saying the detrimental health effects of spraying outweigh the relatively few lives that may be saved, and more environmentally friendly ways of controlling mosquitoes are available. They also question the effectiveness of insecticide spraying, as they believe mosquitoes that are resting or flying above the level of spraying will not be killed; the most common vector in the northeastern United States, Culex pipiens, is a canopy feeder.

Treatment

No specific treatment is available for WNV infection.[76] Most people recover without treatment.[77] In mild cases, over-the-counter pain relievers can help ease mild headaches and muscle aches in adults.[78] In severe cases supportive care is provided, often in hospital, with intravenous fluids, pain medication, respiratory support, and prevention of secondary infections.[79]

Prognosis

While the general prognosis is favorable, current studies indicate that West Nile Fever can often be more severe than previously recognized, with studies of various recent outbreaks indicating that it may take as long as 60 to 90 days to recover.[11] [80] Patients with milder WNF are just as likely as those with more severe manifestations of neuroinvasive disease to experience multiple somatic complaints such as tremor, and dysfunction in motor skills and executive functions for over a year. People with milder symptoms are just as likely as people with more severe symptoms to experience adverse outcomes.[81] Recovery is marked by a long convalescence with fatigue. One study found that neuroinvasive WNV infection was associated with an increased risk for subsequent kidney disease.[82] [83]

Epidemiology

See also: List of West Nile virus outbreaks and West Nile virus in the United States.

WNV was first isolated from a feverish 37-year-old woman at Omogo in the West Nile District of Uganda in 1937 during research on yellow fever virus.[84] A series of serosurveys in 1939 in central Africa found anti-WNV positive results ranging from 1.4% (Congo) to 46.4% (White Nile region, Sudan). It was subsequently identified in Egypt (1942) and India (1953), a 1950 serosurvey in Egypt found 90% of those over 40 years in age had WNV antibodies. The ecology was characterized in 1953 with studies in Egypt[85] and Israel.[86] The virus became recognized as a cause of severe human meningoencephalitis in elderly patients during an outbreak in Israel in 1957. The disease was first noted in horses in Egypt and France in the early 1960s and found to be widespread in southern Europe, southwest Asia and Australia.

The first appearance of WNV in the Western Hemisphere was in 1999[87] with encephalitis reported in humans, dogs, cats, and horses, and the subsequent spread in the United States may be an important milestone in the evolving history of this virus. The American outbreak began in College Point, Queens in New York City and was later spread to the neighboring states of New Jersey and Connecticut. The virus is believed to have entered in an infected bird or mosquito, although there is no clear evidence.[88] West Nile virus is now endemic in Africa, Europe, the Middle East, west and central Asia, Oceania (subtype Kunjin), and most recently, North America and is spreading into Central and South America.[89]

Outbreaks of West Nile virus encephalitis in humans have occurred in Algeria (1994), Romania (1996 to 1997), the Czech Republic (1997), Congo (1998), Russia (1999), the United States (1999 to 2009), Canada (1999–2007), Israel (2000), Greece (2010), and Israel (2024).[90]

Epizootics of disease in horses occurred in Morocco (1996), Italy (1998), the United States (1999 to 2001), and France (2000), Mexico (2003) and Sardinia (2011).

In August 2024 in Warsaw the West Nile virus was identified in bodies of dead birds (Corvidae) while investigating an unusually high number of finds[91] .

Outdoor workers (including biological fieldworkers, construction workers, farmers, landscapers, and painters), healthcare personnel, and laboratory personnel who perform necropsies on animals are at risk of contracting WNV.[92]

In 2012, the US experienced one of its worst epidemics in which 286 people died, with the state of Texas being hard hit by this virus.[93] [94]

Weather

Drought has been associated with a higher number of West Nile virus cases in the following year.[95] As drought can decrease fish and other populations that eat mosquito eggs, higher numbers of mosquitoes can result.[95] Higher temperatures are linked to decreased time for replication and increased viral load in birds and mosquitoes.[96]

Research

A vaccine for horses (ATCvet code:) based on killed viruses exists; some zoos have given this vaccine to their birds, although its effectiveness is unknown. Dogs and cats show few if any signs of infection. There have been no known cases of direct canine-human or feline-human transmission; although these pets can become infected, it is unlikely they are, in turn, capable of infecting native mosquitoes and thus continuing the disease cycle.[97] AMD3100, which had been proposed as an antiretroviral drug for HIV, has shown promise against West Nile encephalitis. Morpholino antisense oligos conjugated to cell penetrating peptides have been shown to partially protect mice from WNV disease.[98] There have also been attempts to treat infections using ribavirin, intravenous immunoglobulin, or alpha interferon.[99] GenoMed, a U.S. biotech company, has found that blocking angiotensin II can treat the "cytokine storm" of West Nile virus encephalitis as well as other viruses.[100]

As of 2019, six vaccines had progressed to human trials but none had been licensed in the United States. Only the two live attenuated vaccines produced strong immunity after a single dose.[101]

External links

Notes and References

  1. Web site: General Questions About West Nile Virus . www.cdc.gov . 26 October 2017 . en-us . 19 October 2017 . live . https://web.archive.org/web/20171026111330/https://www.cdc.gov/westnile/faq/genQuestions.html . 26 October 2017 .
  2. Web site: Symptoms, Diagnosis, & Treatment . www.cdc.gov . 15 January 2019 . en-us . 15 January 2019 . live . https://web.archive.org/web/20171026111330/https://www.cdc.gov/westnile/symptoms/index.html . 26 October 2017 .
  3. Web site: Final Cumulative Maps and Data West Nile Virus CDC. www.cdc.gov. 28 October 2017. en-us. 24 October 2017 . live . https://web.archive.org/web/20171027180705/https://www.cdc.gov/westnile/statsmaps/cumMapsData.html . 27 October 2017 .
  4. Web site: West Nile virus . World Health Organization . 28 October 2017 . July 2011 . live . https://web.archive.org/web/20171018044431/http://www.who.int/mediacentre/factsheets/fs354/en/ . 18 October 2017 .
  5. Web site: Gompf . Sandra . West Nile Virus . Medicine Net . MedicineNet Inc. . 15 January 2019.
  6. Web site: Symptoms, Diagnosis, & Treatment . Centers for Disease Control and Prevention . USA.gov . 15 January 2019. 2018-12-10 .
  7. Web site: West Nile virus . Mayoclinic . Mayo Foundation for Medical Education and Research (MFMER) . 15 January 2019.
  8. Olejnik E . Infectious adenitis transmitted by Culex molestus . Bull Res Counc Isr . 2 . 210–1 . 1952.
  9. Davis LE, DeBiasi R, Goade DE, etal . Sep 2006 . West Nile virus neuroinvasive disease . . 60 . 3 . 286–300 . 16983682 . 10.1002/ana.20959. 30778922 .
  10. Flores Anticona EM, Zainah H, Ouellette DR, Johnson LE . Two case reports of neuroinvasive west nile virus infection in the critical care unit . Case Reports in Infectious Diseases . 2012 . 1–4 . 2012 . 22966470 . 3433121 . 10.1155/2012/839458. free .
  11. Carson PJ, Konewko P, Wold KS, etal . Long-term clinical and neuropsychological outcomes of West Nile virus infection . . 43 . 6 . 723–30 . 2006 . 16912946 . 10.1086/506939 . 2765866 . https://ghostarchive.org/archive/20221009/https://academic.oup.com/cid/article-pdf/43/6/723/933835/43-6-723.pdf . 2022-10-09 . live.
  12. Mojumder, D.K., Agosto, M., Wilms, H. . March 2014 . Is initial preservation of deep tendon reflexes in West Nile Virus paralysis a good prognostic sign? . Neurology Asia . 19 . 1 . 93–97 . etal . 25400704 . 4229851.
  13. Asnis DS, Conetta R, Teixeira AA, Waldman G, Sampson BA . The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience . Clinical Infectious Diseases . 30 . 3 . 413–8 . March 2000 . 10722421 . 10.1086/313737. free .
  14. Montgomery SP, Chow CC, Smith SW, Marfin AA, O'Leary DR, Campbell GL . Rhabdomyolysis in patients with west nile encephalitis and meningitis . Vector-Borne and Zoonotic Diseases . 5 . 3 . 252–7 . 2005 . 16187894 . 10.1089/vbz.2005.5.252. 33442661 .
  15. Smith RD, Konoplev S, DeCourten-Myers G, Brown T . West Nile virus encephalitis with myositis and orchitis . Hum. Pathol. . 35 . 2 . 254–8 . February 2004 . 14991545 . 10.1016/j.humpath.2003.09.007 .
  16. Anninger WV, Lomeo MD, Dingle J, Epstein AD, Lubow M . West Nile virus-associated optic neuritis and chorioretinitis . Am. J. Ophthalmol. . 136 . 6 . 1183–5 . 2003. 14644244 . 10.1016/S0002-9394(03)00738-4.
  17. Paddock CD, Nicholson WL, Bhatnagar J, etal . Fatal hemorrhagic fever caused by West Nile virus in the United States . Clinical Infectious Diseases . 42 . 11 . 1527–35 . June 2006 . 16652309 . 10.1086/503841.
  18. Shaikh S, Trese MT . West Nile virus chorioretinitis . Br J Ophthalmol . 88 . 12 . 1599–60 . 2004 . 15548822 . 1772450 . 10.1136/bjo.2004.049460.
  19. Anderson RC, Horn KB, Hoang MP, Gottlieb E, Bennin B . Punctate exanthem of West Nile Virus infection: report of 3 cases . J. Am. Acad. Dermatol. . 51 . 5 . 820–3 . November 2004 . 15523368 . 10.1016/j.jaad.2004.05.031.
  20. 3337329 . 22309667 . 10.1586/erv.11.180 . 11 . 2 . Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex . 2012 . Expert Rev Vaccines . 177–87 . Lobigs M, Diamond MS .
  21. Web site: Home - PMC - NCBI . 2022-06-24 . www.ncbi.nlm.nih.gov.
  22. Rijks. J.M.. Cito. F.. Cunningham. A.A.. Rantsios. A.T.. Giovannini. A.. Disease Risk Assessments Involving Companion Animals: an Overview for 15 Selected Pathogens Taking a European Perspective. Journal of Comparative Pathology. 155. 1. 2016. S75–S97. 0021-9975. 10.1016/j.jcpa.2015.08.003. 26422413. free.
  23. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL . Epidemiology and transmission dynamics of West Nile virus disease . Emerging Infect. Dis. . 11 . 8 . 1167–73 . 2005 . 16102302 . 10.3201/eid1108.050289a . 3320478 .
  24. Vogels . Chantal Bf . Göertz . Giel P. . Pijlman . Gorben P. . Koenraadt . Constantianus Jm . 2017-11-08 . Vector competence of European mosquitoes for West Nile virus . Emerging Microbes & Infections . 6 . 11 . e96 . 10.1038/emi.2017.82 . 2222-1751 . 5717085 . 29116220.
  25. Kilpatrick . A.M. . Globalization, land use, and the invasion of West Nile virus . Science . 2011. 334. 6054 . 323–327. 22021850 . 3346291 . 10.1126/science.1201010. 2011Sci...334..323K .
  26. Kilpatrick, AM, P Daszak, MJ Jones, PP Marra, LD Kramer. 2006. Host heterogeneity dominates West Nile virus transmission. Proceedings of the Royal Society B: Biological Sciences. 273. 1599. 2327–2333. 10.1098/rspb.2006.3575. 1636093. 16928635.
  27. Kilpatrick, AM, SL LaDeau, PP Marra . Ecology of West Nile virus transmission and its impact on birds in the western hemisphere . Auk . 124 . 4 . 2007 . 1121–1136 . 10.1642/0004-8038(2007)124[1121:eownvt]2.0.co;2. 13796761 . Submitted manuscript .
  28. Komar, N, S Langevin, S Hinten, N Nemeth, E Edwards, D Hettler, B Davis, R Bowen, M Bunning . Experimental infection of North American birds with the New York 1999 strain of West Nile virus . Emerging Infectious Diseases . 9 . 3 . 2003 . 311–322 . 12643825 . 2958552 . 10.3201/eid0903.020628.
  29. Brugman . V. A. . Hernández-Triana . L. M. . England . M. E. . Medlock . J. M. . Mertens . P. P. C. . Logan . J. G. . Wilson . A. J. . Fooks . A. R. . Johnson . N. . Carpenter . S. . 2017-03-27 . Blood-feeding patterns of native mosquitoes and insights into their potential role as pathogen vectors in the Thames estuary region of the United Kingdom . Parasites & Vectors . 10 . 1 . 163 . 10.1186/s13071-017-2098-4 . 1756-3305 . 5369192 . 28347323 . free .
  30. Laboratory-acquired West Nile virus infections—United States, 2002 . MMWR Morb. Mortal. Wkly. Rep.. 51 . 50 . 1133–5 . 2002 . 12537288 . Centers for Disease Control and Prevention (CDC).
  31. Fonseca K, Prince GD, Bratvold J, etal . West Nile virus infection and conjunctive exposure . Emerging Infect. Dis. . 11. 10. 1648–9 . 2005 . 16355512 . 10.3201/eid1110.040212 . 3366727.
  32. Investigation of blood transfusion recipients with West Nile virus infections . MMWR Morb. Mortal. Wkly. Rep. . 51 . 36 . 823 . 2002 . 12269472 . Centers for Disease Control and Prevention (CDC).
  33. West Nile virus infection in organ donor and transplant recipients—Georgia and Florida, 2002 . MMWR Morb. Mortal. Wkly. Rep.. 51 . 35 . 790 . 2002 . 12227442 . Centers for Disease Control and Prevention (CDC).
  34. Intrauterine West Nile virus infection—New York, 2002. MMWR Morb. Mortal. Wkly. Rep. . 51 . 50 . 1135–6 . 2002 . 12537289 . Centers for Disease Control and Prevention (CDC) .
  35. Possible West Nile virus transmission to an infant through breast-feeding—Michigan, 2002 . MMWR Morb. Mortal. Wkly. Rep. . 51. 39. 877–8 . 2002 . 12375687 . Centers for Disease Control and Prevention (CDC) .
  36. Detection of West Nile virus in blood donations—United States, 2003 . MMWR Morb. Mortal. Wkly. Rep. . 52 . 32 . 769–72 . 2003 . 12917583 . Centers for Disease Control and Prevention (CDC) . live . https://web.archive.org/web/20170625121109/https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5232a3.htm . 2017-06-25 .
  37. https://web.archive.org/web/20080820072151/http://www.scotblood.co.uk/westNile.asp West Nile Virus
  38. Web site: West Nile virus. Mayo Clinic. 25 October 2017. live. https://web.archive.org/web/20171026001453/https://www.mayoclinic.org/diseases-conditions/west-nile-virus/symptoms-causes/syc-20350320. 26 October 2017.
  39. Schneider BS, McGee CE, Jordan JM, Stevenson HL, Soong L, Higgs S . Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection . PLOS ONE. 2 . 11 . e1171 . 2007 . 18000543. 10.1371/journal.pone.0001171. 2048662 . Baylis . Matthew. 2007PLoSO...2.1171S . free .
  40. Styer LM, Bernard KA, Kramer LD . Enhanced early West Nile virus infection in young chickens infected by mosquito bite: effect of viral dose . Am. J. Trop. Med. Hyg.. 75 . 2 . 337–45 . 2006 . 16896145 . 10.4269/ajtmh.2006.75.337 . free .
  41. Schneider BS, Soong L, Girard YA, Campbell G, Mason P, Higgs S . Potentiation of West Nile encephalitis by mosquito feeding . Viral Immunol. . 19 . 1. 74–82 . 2006 . 16553552. 10.1089/vim.2006.19.74. 37464180 .
  42. Wasserman HA, Singh S, Champagne DE . Saliva of the Yellow Fever mosquito, Aedes aegypti, modulates murine lymphocyte function. Parasite Immunol. . 26 . 6–7 . 295–306 . 2004. 15541033 . 10.1111/j.0141-9838.2004.00712.x. 32742815.
  43. Limesand KH, Higgs S, Pearson LD, Beaty BJ . Effect of mosquito salivary gland treatment on vesicular stomatitis New Jersey virus replication and interferon alpha/beta expression in vitro . J. Med. Entomol.. 40. 2 . 199–205 . 2003 . 12693849 . 10.1603/0022-2585-40.2.199. 85624297 . free .
  44. Wanasen N, Nussenzveig RH, Champagne DE, Soong L, Higgs S . Differential modulation of murine host immune response by salivary gland extracts from the mosquitoes Aedes aegypti and Culex quinquefasciatus . Med. Vet. Entomol.. 18 . 2 . 191–9 . 2004 . 15189245. 10.1111/j.1365-2915.2004.00498.x. 42458052 .
  45. Zeidner NS, Higgs S, Happ CM, Beaty BJ, Miller BR . Mosquito feeding modulates Th1 and Th2 cytokines in flavivirus susceptible mice: an effect mimicked by injection of sialokinins, but not demonstrated in flavivirus resistant mice. Parasite Immunol. . 21 . 1 . 35–44 . 1999 . 10081770 . 10.1046/j.1365-3024.1999.00199.x. 26774722.
  46. Schneider BS, Soong L, Zeidner NS, Higgs S . Aedes aegypti salivary gland extracts modulate anti-viral and TH1/TH2 cytokine responses to sindbis virus infection . Viral Immunol. . 17 . 4 . 565–73 . 2004. 15671753. 10.1089/vim.2004.17.565.
  47. LM . Bugbee . Forte LR . September 2004 . The discovery of West Nile virus in overwintering Culex pipiens (Diptera: Culicidae) mosquitoes in Lehigh County, Pennsylvania. Journal of the American Mosquito Control Association . 20 . 3 . 326–7 . 15532939.
  48. Goddard LB, Roth AE, Reisen WK, Scott TW . Vertical transmission of West Nile Virus by three California Culex (Diptera: Culicidae) species . J. Med. Entomol. . 40 . 6 . 743–6 . November 2003 . 14765647 . 10.1603/0022-2585-40.6.743 . free .
  49. Kumar D, Drebot MA, Wong SJ, etal . A seroprevalence study of West Nile virus infection in solid organ transplant recipients . Am. J. Transplant. . 4. 11 . 1883–8 . 2004 . 15476490 . 10.1111/j.1600-6143.2004.00592.x . 31695008 .
  50. Jean CM, Honarmand S, Louie JK, Glaser CA . Risk factors for West Nile virus neuroinvasive disease, California, 2005 . Emerging Infect. Dis. . 13 . 12 . 1918–20 . December 2007 . 18258047 . 2876738 . 10.3201/eid1312.061265 .
  51. Kumar D, Drebot MA, Wong SJ, etal . A seroprevalence study of west nile virus infection in solid organ transplant recipients . Am. J. Transplant. . 4. 11 . 1883–8 . 2004 . 15476490 . 10.1111/j.1600-6143.2004.00592.x . 31695008 .
  52. WG . Glass . Lim JK . Cholera R . Pletnev AG . Gao JL . Murphy PM . October 17, 2005 . Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection . Journal of Experimental Medicine . 202 . 8 . 1087–98 . 16230476 . 10.1084/jem.20042530 . 2213214.
  53. WG . Glass . McDermott DH . Lim JK . Lekhong S . Yu SF . Frank WA . Pape J . Cheshier RC . Murphy PM . January 23, 2006 . CCR5 deficiency increases risk of symptomatic West Nile virus infection . Journal of Experimental Medicine . 203 . 1 . 35–40 . 16418398 . 10.1084/jem.20051970 . 2118086.
  54. Web site: Safety and Health Information Bulletins Workplace Precautions Against West Nile Virus Occupational Safety and Health Administration. www.osha.gov. en-us. 2018-11-28.
  55. Web site: West Nile virus. World Health Organization. en-US. 2018-11-28.
  56. Book: Rea . William J. . Reversibility of Chronic Disease and Hypersensitivity, Volume 5: Treatment Options of Chemical Sensitivity . Patel . Kalpana D. . 2017-12-14 . CRC Press . 978-1-4987-8137-4 . 699–700 . en.
  57. Tyler KL, Pape J, Goody RJ, Corkill M, Kleinschmidt-DeMasters BK . CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis . Neurology . 66 . 3 . 361–5 . February 2006 . 16382032 . 10.1212/01.wnl.0000195890.70898.1f . 37751889 .
  58. Web site: 2012 DOHMH Advisory #8: West Nile Virus . New York City Department of Health and Mental Hygiene . June 28, 2012 . live . https://web.archive.org/web/20131203000040/http://www.nyc.gov/html/doh/downloads/pdf/cd/2012/12md08.pdf . December 3, 2013 .
  59. Papa A, Karabaxoglou D, Kansouzidou A . Acute West Nile virus neuroinvasive infections: cross-reactivity with dengue virus and tick-borne encephalitis virus . J. Med. Virol. . 83 . 10 . 1861–5 . October 2011 . 21837806 . 10.1002/jmv.22180 . 9901472 .
  60. Book: Turgeon, Mary Louise . Immunology & Serology in Laboratory Medicine - E-Book . 2017-04-07 . Elsevier Health Sciences . 978-0-323-40283-5 . 252 . en.
  61. Book: Long . Sarah S. . Principles and Practice of Pediatric Infectious Diseases . Prober . Charles G. . Fischer . Marc . 2017-05-09 . Elsevier Health Sciences . 978-0-323-46132-0 . 1135 . en.
  62. Web site: Prevention West Nile Virus CDC. 2018-09-24. www.cdc.gov. en-us. 2018-11-28.
  63. Web site: American Academy of Pediatrics. Choosing an Insect Repellent for Your Child. healthychildren.org. 24 August 2016. 8 August 2012. live. https://web.archive.org/web/20160827225733/https://www.healthychildren.org/English/safety-prevention/at-play/Pages/Insect-Repellents.aspx. 27 August 2016.
  64. Web site: Prevention West Nile Virus CDC. 2018-09-24. www.cdc.gov. en-us. 2018-10-29.
  65. Book: Richman . Douglas D. . Clinical Virology . Whitley . Richard J. . Hayden . Frederick G. . 2016-12-01 . John Wiley & Sons . 978-1-68367-316-3 . en.
  66. Book: Auerbach, Paul S. . Medicine for the Outdoors: The Essential Guide to First Aid and Medical Emergencies . 2009-01-01 . Elsevier Health Sciences . 978-0-323-06813-0 . 392 . en.
  67. M . Jozan . Evans R . McLean R . Hall R . Tangredi B . Reed L . Scott J . Fall 2003 . Detection of West Nile virus infection in birds in the United States by blocking ELISA and immunohistochemistry . Vector-Borne and Zoonotic Diseases . 3 . 3 . 99–110 . 14511579 . 10.1089/153036603768395799. 17720540 . Submitted manuscript .
  68. RA . Hall . Broom AK . Hartnett AC . Howard MJ . Mackenzie JS . February 1995 . Immunodominant epitopes on the NS1 protein of MVE and KUN viruses serve as targets for a blocking ELISA to detect virus-specific antibodies in sentinel animal serum . Journal of Virological Methods . 51 . 2–3 . 201–10 . 7738140 . 10.1016/0166-0934(94)00105-P.
  69. Web site: California Department of Public Health Tutorial for Local Agencies to Safely Collect Dead Birds Oral Swab Samples on RNAse Cards for West Nile Virus Testing . dead . https://web.archive.org/web/20140709075706/http://westnile.ca.gov/downloads.php?download_id=2949&filename=RNAse_tutorial.pdf . July 9, 2014.
  70. http://www.fortiusbio.com/RNA_Sampling_Card.html RNA virus preserving filter paper card
  71. Book: Dusfour . Isabelle . Mosquitopia: The place of pests in a healthy world . Chaney . Sarah C . . 2022 . 978-1-00-305603-4 . New York . 213–233 . English . 14 - MOSQUITO CONTROL: Success, failure and expectations in the context of arbovirus expansion and emergence .
  72. Tidi . Stephen K . December 6, 2015 . Mosquito control: A review . Biosciences Research in Today's World . 2476-7905.
  73. Wooding . Madelien . Naudé . Yvette . Rohwer . Egmont . Bouwer . Marc . 2020-02-17 . Controlling mosquitoes with semiochemicals: a review . Parasites & Vectors . en . 13 . 1 . 80 . 10.1186/s13071-020-3960-3 . free . 1756-3305 . 7027039 . 32066499.
  74. Karunaratne . S. H. P. P. . Surendran . S. N. . 2022 . Mosquito control: A review on the past, present and future strategies . Journal of the National Science Foundation of Sri Lanka . 50 . 277 . 10.4038/jnsfsr.v50i0.11244 . en. free .
  75. Dahmana . Handi . Mediannikov . Oleg . March 13, 2020 . Mosquito-Borne Diseases Emergence/Resurgence and How to Effectively Control It Biologically . Pathogens . en . 9 . 4 . 310 . 10.3390/pathogens9040310 . free . 32340230 . 7238209 . 2076-0817.
  76. Petersen LR, Brault AC, Nasci RS . West Nile virus: review of the literature . JAMA . 310 . 3 . 308–15 . July 2013 . 23860989 . 4563989 . 10.1001/jama.2013.8042 .
  77. Web site: West Nile Virus. MedlinePlus. 18 March 2021. 21 October 2021.
  78. Web site: 2021-07-22 . Symptoms, Diagnosis, & Treatment West Nile Virus CDC . 2022-06-24 . www.cdc.gov . en-us.
  79. Sambri V, Capobianchi M, Charrel R, Fyodorova M, Gaibani P, Gould E, Niedrig M, Papa A, Pierro A, Rossini G, Varani S, Vocale C, Landini MP . West Nile virus in Europe: emergence, epidemiology, diagnosis, treatment, and prevention . Clin Microbiol Infect . 19 . 8 . 699–704 . August 2013 . 23594175 . 10.1111/1469-0691.12211 . free .
  80. Watson JT, Pertel PE, Jones RC, etal . Clinical characteristics and functional outcomes of West Nile Fever . Ann. Intern. Med. . 141 . 5 . 360–5 . September 2004 . 15353427 . 10.7326/0003-4819-141-5-200409070-00010. 5779034 .
  81. Klee AL, Maidin B, Edwin B, etal . Aug 2004 . Long-term prognosis for clinical West Nile virus infection . Emerg Infect Dis . 10 . 8. 1405–11 . 15496241 . 10.3201/eid1008.030879 . 3320418 .
  82. Nolan MS, Podoll AS, Hause AM, Akers KM, Finkel KW, Murray KO . Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort . PLOS ONE . 7 . 7 . e40374 . 2012 . 22792293 . 3391259 . 10.1371/journal.pone.0040374 . Wang . Tian. 2012PLoSO...740374N . free .
  83. Web site: New Study Reveals: West Nile virus is far more menacing & harms far more people . 26 August 2012 . The Guardian Express . 26 August 2012 . live . https://web.archive.org/web/20121006012354/http://guardianlv.com/2012/08/new-study-reveals-west-nile-virus-is-far-more-menacing-harms-far-more-people/ . 6 October 2012 .
  84. Smithburn KC, Hughes TP, Burke AW, Paul JH . A Neurotropic Virus Isolated from the Blood of a Native of Uganda . Am. J. Trop. Med. . 20 . 1. 471–92 . June 1940. 10.4269/ajtmh.1940.s1-20.471 . free .
  85. Work TH, Hurlbut HS, Taylor RM . Isolation of West Nile virus from hooded crow and rock pigeon in the Nile delta . Proc. Soc. Exp. Biol. Med. . 84 . 3. 719–22 . 1953 . 13134268 . 10.3181/00379727-84-20764 . 45962741 .
  86. Bernkopf H, Levine S, Nerson R . Isolation of West Nile virus in Israel . J. Infect. Dis. . 93 . 3 . 207–18 . 1953. 13109233 . 10.1093/infdis/93.3.207 .
  87. Nash D, Mostashari F, Fine A, etal . The outbreak of West Nile virus infection in the New York City area in 1999 . N. Engl. J. Med. . 344 . 24 . 1807–14 . June 2001 . 11407341 . 10.1056/NEJM200106143442401. free .
  88. Calisher CH . Charles Calisher. West Nile virus in the New World: appearance, persistence, and adaptation to a new econiche—an opportunity taken . Viral Immunol.. 13 . 4 . 411–4 . 2000 . 11192287 . 10.1089/vim.2000.13.411 .
  89. Book: Encyclopedia of Environmental Health . 2019-08-22 . Elsevier . 978-0-444-63952-3 . 452 . en.
  90. Book: Bisen . Prakash S. . Emerging Epidemics: Management and Control . Raghuvanshi . Ruchika . 2013-06-14 . John Wiley & Sons . 978-1-118-39325-3 . en.
  91. Web site: Tajemnicza choroba ptaków w Warszawie. Potwierdziły się złe informacje. August 13, 2024.
  92. Web site: West Nile virus. August 27, 2012. NIOSH. live. https://web.archive.org/web/20170729073111/https://www.cdc.gov/niosh/topics/westnile/. July 29, 2017.
  93. Murray KO, Ruktanonchai D, Hesalroad D, Fonken E, Nolan MS . West Nile virus, Texas, USA, 2012 . Emerging Infectious Diseases . 19 . 11 . 1836–8 . November 2013 . 24210089 . 3837649 . 10.3201/eid1911.130768 .
  94. News: 2012 was deadliest year for West Nile in US, CDC says. Fox, M.. NBC News. May 13, 2013. May 13, 2013. live. https://web.archive.org/web/20130608042431/http://vitals.nbcnews.com/_news/2013/05/13/18232095-2012-was-deadliest-year-for-west-nile-in-us-cdc-says. June 8, 2013.
  95. Brown. L.. Medlock. J.. Murray. V.. January 2014. Impact of drought on vector-borne diseases – how does one manage the risk?. Public Health. 128. 1. 29–37. 10.1016/j.puhe.2013.09.006. 24342133. 0033-3506.
  96. Paz. Shlomit. 2015-04-05. Climate change impacts on West Nile virus transmission in a global context. Philosophical Transactions of the Royal Society B: Biological Sciences. 370. 1665. 20130561. 10.1098/rstb.2013.0561. 0962-8436. 25688020. 4342965.
  97. Web site: Vertebrate Ecology . 30 April 2009 . West Nile Virus . Division of Vector-Borne Diseases, CDC . live . https://web.archive.org/web/20130301003126/http://www.cdc.gov/ncidod/dvbid/westnile/birds%26mammals.htm . 1 March 2013 .
  98. Tia S . Deas . Bennett CJ . Jones SA . Tilgner M . Ren P . Behr MJ . Stein DA . Iversen PL . Kramer LD . Bernard KA . Shi PY . May 2007 . In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus . Antimicrob Agents Chemother . 17485503 . 10.1128/AAC.00069-07 . 51 . 2470–82 . 7 . 1913242.
  99. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL . Virology, pathology, and clinical manifestations of West Nile virus disease . Emerging Infect. Dis. . 11 . 8 . 1174–9 . 2005 . 16102303 . 10.3201/eid1108.050289b . 3320472 .
  100. Moskowitz DW, Johnson FE . The central role of angiotensin I-converting enzyme in vertebrate pathophysiology . Curr Top Med Chem . 4 . 13 . 1433–54 . 2004 . 15379656 . 10.2174/1568026043387818 . 22897898 .
  101. Book: Malik . Yashpal Singh . Role of Birds in Transmitting Zoonotic Pathogens . Milton . Arockiasamy Arun Prince . Ghatak . Sandeep . Ghosh . Souvik . 2022-01-01 . Springer Nature . 978-981-16-4554-9 . 49 . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "West Nile fever".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.